NLS Pharmaceutics AG (NLSP)

NLS Pharmaceutics AG Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Assets

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Jun 30, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Cash & Equivalents	3.07	1.67	0.9	8.95	5.43	0.09
Cash & Short-Term Investments	3.07	1.67	0.9	8.95	5.43	0.09
Cash Growth	455.83%	85.52%	-89.97%	64.76%	5695.69%	-57.46%
Other Receivables	0.57	0.45	0.04	0.04	0.04	0.06
Receivables	0.57	0.45	0.04	0.04	0.04	0.06
Prepaid Expenses	0.37	0.05	0.07	0.19	0.22	0.01
Other Current Assets	0.02	0.07	0.82	0.07	0.04	0.03
Total Current Assets	4.04	2.23	1.82	9.25	5.72	0.2
Property, Plant & Equipment	0.01	0.01	0.01	0.02	0.03	-
Long-Term Deferred Charges	0.3	-	-	-	-	0.95
Other Long-Term Assets	0	0	0.02	0.01	0.01	0.07
Total Assets	4.34	2.23	1.85	9.28	5.76	1.21

Liabilities

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Jun 30, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Accounts Payable	1.02	0.52	4.63	2.37	1.74	4.01
Accrued Expenses	0.43	0.31	1.54	0.97	0.65	1.25
Short-Term Debt	-	-	1.63	-	-	1.16
Current Portion of Long-Term Debt	-	-	-	-	-	0.61
Other Current Liabilities	-	-	0.11	0.01	0.02	0.18
Total Current Liabilities	1.46	0.83	7.92	3.36	2.4	7.2
Long-Term Debt	-	-	-	-	-	0.31
Long-Term Unearned Revenue	-	-	2.5	2.5	2.5	2.5
Pension & Post-Retirement Benefits	-	-	0.26	0.14	0.32	0.18
Total Liabilities	1.46	0.83	10.68	6	5.22	10.2

Shareholders' Equity

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Jun 30, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Common Stock	0.15	0.17	0.67	0.67	0.34	0.15
Additional Paid-In Capital	77.36	72.82	61.03	60.86	42.08	20.65
Retained Earnings	-74.81	-74.43	-70.37	-58.2	-41.71	-29.76
Treasury Stock	-	-	-	-	-0.03	-
Comprehensive Income & Other	0.11	0.11	-0.16	-0.05	-0.15	-0.02
Total Common Equity	2.82	-1.33	-8.83	3.28	0.54	-8.98
Shareholders' Equity	2.88	1.41	-8.83	3.28	0.54	-8.98
Total Liabilities & Equity	4.34	2.23	1.85	9.28	5.76	1.21

Additional Metrics

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Jun 30, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Total Debt	-	-	1.63	-	-	2.08
Net Cash (Debt)	3.07	1.67	-0.74	8.95	5.43	-1.99
Net Cash Growth	-	-	-	64.76%	-	-
Net Cash Per Share	1.02	1.08	-0.77	18.19	18.25	-11.44
Filing Date Shares Outstanding	4.15	3.16	1	0.81	0.37	0.3
Total Common Shares Outstanding	4.15	3.16	0.81	0.81	0.37	0.17
Working Capital	2.58	1.4	-6.1	5.89	3.32	-7.01
Book Value Per Share	0.68	-0.42	-10.90	4.05	1.47	-51.63
Tangible Book Value	2.82	-1.33	-8.83	3.28	0.54	-8.98
Tangible Book Value Per Share	0.68	-0.42	-10.90	4.05	1.47	-51.63
Machinery	-	0.02	0.01	0.01	0.01	-

SEC Filings: 10-K · 10-Q

Data Source: S&P Global Market Intelligence Last updated: Jun 30, 2025

Financial data is provided by S&P Global Market Intelligence and updates within hours after each earnings release, which is every six months for this company.

Update frequency:

Semi-annually

Last checked:

Jan 1, 2000

Data Sources Report a data error